Product Description
Mechanisms of Action: NK3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Schizophrenia|Irritable Bowel Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT00300963 | P2 |
Completed |
Schizophrenia |
2005-10-01 |
|
SB-223412/093 | P2 |
Completed |
Schizophrenia |
2005-10-01 |
|
2004-000848-24 | P2 |
Completed |
Irritable Bowel Syndrome |
2005-07-26 |
|
NCT00101985 | P2 |
Completed |
Irritable Bowel Syndrome |
2005-07-01 |